Text Size
A A A
U. S. Department of Health and Human Services
Skip Navigation

Home > RePORTER > Project Information

Project InformationProject Information Help

Project Number: 5R01DA012854-10 Contact PI / Project Leader: MADDEN, PAMELA ANN
Title: THE GENETICS OF VULNERABILITY TO NICOTINE ADDICTIONS Awardee Organization: WASHINGTON UNIVERSITY
Description
Abstract Text:
DESCRIPTION (provided by applicant): Long-term smoking is the leading preventable cause of cancers and of premature mortality, with approximately one billion smoking-related deaths projected globally, based on present trends, in the current century. This is the re-revised (A2) competing continuation of a genetic epidemiologic collaboration to identify genes that influence risks for heavy smoking and nicotine dependence. During the first five-year funding period, QTL linkage analyses using 10cM microsatellite marker genome scan data have identified a strong linkage signal in both Australian and Finnish sibships, for our primary heaviness-of-smoking (HoS) phenotype, on Chr 22q12 (in updated analyses, multi-point LODs of 3.05 and 3.21 respectively). Genotyping of two additional microsatellite markers flanking the linkage peaks, in both Finnish and Australian genome-scan samples, yielded a combined multipoint LOD of 5.21 (genome-wide significance p=.006) at 25cM. This competing continuation seeks to identify the gene or genes at 22q12 which are contributing to HoS using the efficiency of existing data and DNAs and large informative samples, with complementary strengths, that were drawn from the same populations in which the original linkage signal was obtained. This goal will be achieved by (i) conducting a genetic association study, with high-throughput genotyping of 1436 SNPs across a 1-LOD support interval within our primary linkage region in 1000 unrelated Finnish male heavy smokers (ATBC chemoprevention trial participants who smoked 40+ cigarettes per day) and 1000 Finnish male population controls (Health2000 participants) (Aim 1: 'Finnish series I'; 'stage 1 genotyping'); (ii) conducting follow-up genotyping of SNPs found nominally significant at stage 1 in two separate series: (a) an additional 2000 unrelated heavy smokers (who smoked 30+ cigarettes per day) and 2000 population controls ('Finnish series II'); and (b) a family-based series of 4429 siblings who are smokers (55 percent female) from a community-based series of Australian large sibships ('BIGSIB' sample) ascertained solely on the basis of large sibship size from the Australian twin panel, from the same cohorts as the Australian linkage families (Aim 2: 'stage 2 genotyping'). Combining Finnish series I and II will ensure adequate power to detect quite modest QTL effect sizes; confirmation of nominal stage 1 associations in the Australian series will ensure that we are able to detect genetic effects that may be only modest in male long-term smokers, but more potent in female smokers. For genes with SNPs confirmed to be associated with HoS, we will conduct DNA sequencing in individuals with high-risk and low-risk haplotypes, selected from the original Finnish and Australian linkage families, to attempt to identify variants that might be functional (Aim 3), and will characterize using family-based association approaches the effects of genetic variants (or haplotypes) thus identified on cigarette-smoking and related behaviors (including correlated substance use and other psychiatric disorders), using the original Finnish NAG families and the Australian BIGSIB sample (Aim 4). The importance of genetic influences on risk of becoming a long-term heavy smoker has been known for many years. Understanding the genetic mechanisms by which some individuals are at increased risk should ultimately lead to improved therapies to assist smoking cessation.
Project Terms:
22q12; Accounting; ADRBK2 gene; Alcohol or Other Drugs use; alpha Tocopherol; Australia; base; Behavior; Beta Carotene; Beta-Adrenergic Receptor Kinase 2; Biological; cancer chemoprevention; Cancer Etiology; Candidate Disease Gene; Cessation of life; Chemoprevention; Chromosomes; Chromosomes, Human, Pair 22; Cigarette; cigarette smoking; cohort; Collaborations; Communities; Consumption; Data; Data Set; density; DNA; DNA Sequence; Ensure; Epidemiology; Family; family genetics; Female; Finland; follow-up; Funding; Genes; Genetic; genetic association; genetic epidemiology; genetic linkage; genetic linkage analysis; Genetic Predisposition to Disease; genetic variant; Genome Scan; genome-wide; Genotype; Goals; Haplotypes; high risk; Hour; improved; indexing; Individual; Lead; male; Malignant neoplasm of lung; Measures; Mental disorders; Microsatellite Repeats; Nicotine Dependence; novel; Parents; Participant; Phase; Phenotype; Population; Population Control; Premature Mortality; Psychopathology; Quantitative Trait Loci; Recruitment Activity; response; Risk; Sampling; Series; Severities; Siblings; Signal Transduction; Smoke; Smoker; Smoking; smoking cessation; Smoking History; SNP genotyping; Source; Specificity; Staging; Symptoms; Tobacco; trend; Twin Multiple Birth; Update; Variant



The RePORTER database is available to all public users at http://exporter.nih.gov/. As the data are available for bulk download, the RePORTER system reserves the right to block IP addresses that fail to adhere to instructions in the system’s robots.txt files or submit requests at a rate that negatively impacts service delivery to other users. RePORTER reserves the right to terminate any automated query to the RePORTER application that negatively affects service delivery to other users.

Page Last Updated on February 17, 2013
This site is best viewed with Internet Explorer (7.0 or higher) or Mozilla Firefox (3.0).

NIH...Turning Discovery Into Health®
RePORTER2